Zogenix Slips Seizure Drug Stock-Drop Claims For Now
Biopharma company Zogenix has escaped claims for now that it failed its investors by submitting a deficient application for a seizure drug to the U.S. Food and Drug Administration, a California...To view the full article, register now.
Already a subscriber? Click here to view full article